International Stem Cell files draft information statement for Lifeline Cell Technology sale to ATCC

International Stem Cell shareholders authorized the sale of 100% of Lifeline Cell Technology membership interests to ATCC under a July 10, 2026 agreement.

The transaction is valued at $25 million in cash, subject to working capital, cash and debt adjustments, with a $2.5 million indemnity escrow and a $100,000 adjustment escrow.

Net cash proceeds are estimated at about $22.1 million. Intended use includes working capital and general corporate purposes.

Closing is targeted for Q3 2026 and is expected to occur on the second business day after closing conditions are met or waived.